ReviewEuropean respiratory review : an official journal of the European Respiratory Society2010
Mucoactive drugs.
Review in European respiratory review : an official journal of the European Respiratory Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06377410 (A Randomised, Open Label, Interventional Study Evaluating the Efficacy & Safety of Dry Powder Ivy Extract), which is not on this map. Cited by 65 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Open Label, Interventional Study Evaluating the Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients (SyProNAC Trial)
Who cites it
65 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Effect of inhaled anticholinergics on bronchial secretions: a systematic review.Frontiers in physiology · 2026Pooled it
- Mucolytics for children with chronic suppurative lung disease.The Cochrane database of systematic reviews · 2025Pooled it
- Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis.Thorax · 2020Pooled it
- Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).International journal of chronic obstructive pulmonary disease · 2018Guideline
- Mucolytics for bronchiectasis.The Cochrane database of systematic reviews · 2014Pooled it
- Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children: A multicenter, non-inferiority, prospective, randomized controlled trial.Acta pharmaceutica Sinica. B · 2024Trial
- Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.The European respiratory journal · 2017Trial
- Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.PloS one · 2016Trial
- Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms.Respiratory research · 2012Trial
- Carbocisteine Reduces Airway Mucus Obstruction and Alters Inflammatory Cell Populations in a Model of Muco-Obstructive Lung Disease.Immunology and cell biology · 2026Article
- Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.Biomedicines · 2026Review
- Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale.Geriatrics & gerontology international · 2026Review
- Thermally assisted microbot transport through high-viscosity media.Scientific reports · 2025Article
- Association between early administration of mucoactive agents and in-hospital mortality in patients with pneumonia requiring mechanical ventilation: a nationwide cohort study.Journal of intensive care · 2025Article
- Carbon Dots with Tunable Charge as Mucus-Penetrating Gene Carriers.Pharmaceutics · 2025Article
- Effects of Adjuvant Respiratory Therapy on Secretion Expectoration and Treatment Adherence in Patients with Head and Neck Cancer Receiving Concurrent Chemo-Radiotherapy.Medicina (Kaunas, Lithuania) · 2025Article
- Efficacy of EA575 as an Antitussive and Mucoactive Agent in Preclinical In Vivo Models.Biomedicines · 2025Article
- Article
- Observational
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucus hypersecretion is a clinical feature of severe respiratory diseases such as asthma, cystic fibrosis and chronic obstructive pulmonary disease. Airway mucosal infection and/or inflammation associated with these diseases often gives rise to inflammatory products, including neutrophil-derived DNA and filamentous actin, in addition to bacteria, apoptotic cells and cellular debris, that may collectively increase mucus production and viscosity. Mucoactive agents have been the medication of choice for the treatment of respiratory diseases in which mucus hypersecretion is a clinical complication. The main purpose of mucoactive drugs is to increase the ability to expectorate sputum and/or decrease mucus hypersecretion. Many mucoactive drugs are currently available and can be classified according to their putative mechanism of action. Mucoactive medications include expectorants, mucoregulators, mucolytics and mucokinetics. By developing our understanding of the specific effects of mucoactive agents, we may result in improved therapeutic use of these drugs. The present review provides a summary of the most clinically relevant mucoactive drugs in addition to their potential mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.